CURRENT CONCEPTS OF COMORBID CONDITIONS IN METABOLICALLY ASSOCIATED FATTY LIVER DISEASE

Abstract

Current scientific data regarding the role of metabolic abnormalities in the development and progression of metabolically associated fatty liver disease, as well as the assessment of existing approaches to their management, have been analyzed. It is demonstrated that dyslipidemia, insulin resistance, and obesity are not only key risk factors for the development of metabolically associated fatty liver disease but also contribute to increased cardiovascular morbidity and mortality in this patient population. Current non-pharmacological and pharmacological therapeutic strategies aimed at correcting metabolic abnormalities and reducing the risk of disease progression are reviewed.